SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 7/22/2016 3:35:07 PM - Followers: 166 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Current Report Filing (8-k) 07/22/2016 04:12:17 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/19/2016 03:25:59 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/19/2016 03:22:02 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/19/2016 03:16:36 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 07/19/2016 03:12:05 PM
News News Alert: Current Report Filing (8-k) 07/22/2016 04:12:17 PM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8361   Yep,... They are. So either they are not drkazmd65 07/22/16 03:35:07 PM
#8360   Aren't they obliged to report it if the Kami_ss 07/22/16 01:51:03 PM
#8359   It's been going down for over 20 years crtdude 07/22/16 09:45:37 AM
#8358   You are generally right about that. But let's Kami_ss 07/22/16 08:36:31 AM
#8357   Your missing the most important point--- they didn't Turney 07/22/16 07:59:34 AM
#8356   Ah wasn't trying to mislead, new to the Nacho15 07/22/16 06:39:40 AM
#8355   They did not buy - they were distributed crtdude 07/22/16 06:30:19 AM
#8354   Insider buying always a good sign Nacho15 07/21/16 02:54:31 PM
#8353   Don't know, hope so, and I will be Paleman 07/20/16 02:20:45 PM
#8352   Anyone think big announcements coming at the shareholders meeting? trickledownfacists 07/20/16 12:11:18 PM
#8351   Yeah, saw that a bit ago. Made trickledownfacists 07/19/16 09:25:25 AM
#8350   Here's a tidbit about Kersten I just found Turney 07/19/16 08:08:22 AM
#8349   Gives me a little hope for the HPV trickledownfacists 07/18/16 02:27:42 PM
#8348   Much quieter trading so far today,.... drkazmd65 07/15/16 10:36:49 AM
#8347   Quite the purchase right before the shareholder meeting.... trickledownfacists 07/14/16 11:20:39 PM
#8346   Yeah, solid! Hadn't seen that for a while Kami_ss 07/14/16 12:14:09 PM
#8345   Quite the buy, 400k. Volume rising. trickledownfacists 07/14/16 11:52:58 AM
#8344   Agreed, however I believe any word on arbitration trickledownfacists 07/13/16 10:41:48 PM
#8343   The price action from .44 to .48 is Turney 07/13/16 07:57:43 PM
#8342   It would be great to see enrollment complete trickledownfacists 07/13/16 05:58:18 PM
#8341   http://vignette4.wikia.nocookie.net/braveheart/images/7/7c/Stirling.jpg/rev Foxwoods Man 07/13/16 12:43:27 PM
#8340   Way more civil here. trickledownfacists 07/13/16 11:00:11 AM
#8339   You are right, Im not too proud that xdrt91 07/13/16 10:57:40 AM
#8338   Agreed with your assessment of what Yahoo! did drkazmd65 07/13/16 10:32:38 AM
#8337   Hi Dr K, its good to see a xdrt91 07/13/16 10:13:32 AM
#8336   Been in the wilderness..... Good news trickledownfacists 07/12/16 11:28:22 AM
#8335   That's a pretty solid thing to have in drkazmd65 07/11/16 10:19:42 AM
#8334   Cel-Sci Reports European Patent On Cancer Drug overlordpeter 07/11/16 08:40:30 AM
#8333   CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy Foxwoods Man 07/11/16 08:28:15 AM
#8332   here is an interesting article just to show NSchai1 Beethoven 07/07/16 03:53:43 PM
#8331   Hahaha, sure, why not! The silver line Kami_ss 07/06/16 05:06:09 PM
#8330   2783.... as a result of the Cel0Sci LEAPs year. mogman 07/06/16 04:52:22 PM
#8329   I heard 2782....did you hear about a year Foxwoods Man 07/05/16 04:01:33 PM
#8328   True, I hope 880 patients gives the stock Kami_ss 07/05/16 10:42:29 AM
#8327   Agreed - I was 'predicting' 29 if I drkazmd65 07/05/16 09:47:24 AM
#8326   Not bad... back on track Kami_ss 07/05/16 09:18:55 AM
#8325   CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or Foxwoods Man 07/05/16 09:15:40 AM
#8324   Probably Tuesday trickledownfacists 07/01/16 08:17:31 PM
#8323   No numbers... ?! Kami_ss 07/01/16 06:32:40 PM
#8322   The thing is the summer holidays for docs Kami_ss 07/01/16 09:34:59 AM
#8321   Yup, would like to see them before the open.... trickledownfacists 07/01/16 09:12:32 AM
#8320   I can't guess really... But better be good Kami_ss 07/01/16 09:07:50 AM
#8319   I will be optimistic for a change and Foxwoods Man 07/01/16 06:21:22 AM
#8318   24 trickledownfacists 07/01/16 12:05:00 AM
#8317   Yeah sell to settle, but no one would trickledownfacists 06/30/16 10:43:00 PM
#8316   Yeah in the twenties. trickledownfacists 06/30/16 10:42:09 PM
#8315   So,... Any guesses as to number of June drkazmd65 06/30/16 09:50:09 PM
#8314   Unlikely, but perhaps the inverse. Sell to settle. jap1511 06/30/16 06:18:40 PM
#8313   Why do you think it is interesting? ducruacuteo11 06/30/16 05:41:57 PM
#8312   Very interesting.,,,, Thomas H. Lee’s InVentiv Said to Pursue trickledownfacists 06/29/16 10:34:30 PM
PostSubject